Prioritising suspected MDR-TB sputum in Australian laboratories
Tuberculosis laboratories need a dependable pathway for people whose sputum may contain multidrug-resistant Mycobacterium tuberculosis. A positive finding can trigger urgent treatment changes, contact management and infection-control measures, yet specimens may reach the laboratory after collection delays, fragmented transport or a crowded overnight workload. The GLI Quality Tool offers a useful foundation: its four-phase roadmap supports establishment and improvement of quality management systems through twelve Quality Systems Essentials. Checklists, user instructions and downloadable materials can be adapted to laboratories with different staffing levels and budgets.
Triage is a prioritisation process, not a substitute for diagnostic testing. It identifies specimens requiring rapid handling while preserving accuracy, safety and traceability for every sample. Previous tuberculosis treatment, possible exposure to drug-resistant disease, treatment failure or clinical deterioration may justify priority under local protocols, but none proves MDR-TB. Risk assessment should combine clinical and exposure history with specimen quality, and demographic characteristics alone should never be used to infer resistance.
Australia’s geography shapes the task. Public hospital laboratories and private providers, including Path Labs and Sonic Healthcare’s Australian Clinical Labs, serve communities including Sydney, Melbourne, Brisbane, Perth, Adelaide and regional centres. Many patients first reach testing through a general practitioner, emergency department or respiratory clinic, so requests may arrive with incomplete histories. Specimens can move through hospital couriers, interstate freight or flights, with summer heat in Perth and tropical conditions in northern Australia making transport validation important. First Nations patients may enter care through Aboriginal Community Controlled Health Organisations, rural hospitals or Remote Area Medical Services, so the same triage rules must work at receiving and remote sites.
Tuberculosis is notifiable through state and territory communicable-disease systems, with drug-resistant disease included in national surveillance. Diagnostic devices used in Australia are regulated under the Therapeutic Goods Act 1989 and overseen by the TGA, while NATA accreditation against ISO/IEC 15189 provides a recognised quality benchmark. A practical workflow for triaging high-priority sputum from suspected MDR-TB patients must therefore connect bench priorities with notification, clinical escalation and nationally consistent expectations, rather than depend on an informal rush system.
Set triage rules before the specimen arrives
Start with the request. Record identifiers, collection date and time, specimen type and volume, relevant symptoms, previous TB treatment, possible exposure to drug-resistant TB, antimicrobial exposure and the clinician’s reason for suspecting MDR-TB. Confirm whether sputum was expectorated rather than saliva and whether serial samples are still expected. Clinical information should reach the bench with the sample, not be reconstructed after a result. A structured request also reduces anxiety for patients and staff while supporting an auditable priority decision.
Convert these data into time-bound lanes. A same-shift lane might cover suspected infectious pulmonary TB, previous treatment failure or a specimen received after a documented collection or transport delay. A second lane can hold routine samples while preserving urgent culture work, and a clarification lane handles incomplete or nonconforming submissions. Define who can assign priority, how quickly each lane moves, and what happens if an urgent result is unavailable. Reception staff should flag specimens without changing their diagnostic meaning, and rejected or unlabelled samples should trigger direct contact with the collector rather than silent disposal.
Create a rapid testing and escalation lane
Within the high-priority lane, validate and perform a rapid nucleic-acid amplification test for M. tuberculosis complex and rifampicin resistance, such as Xpert MTB/RIF or an equivalent platform listed by the TGA for the intended use. Work with the treating team to collect adequate sputum before antibiotics where this can be done safely, while recognising that treatment should not be delayed for laboratory convenience. The result should be available within the laboratory’s stated turnaround commitment, with invalid repeats, instrument errors and rejected specimens recorded as quality events.
Microscopy remains useful for infectiousness assessment and workload planning, but a negative smear cannot exclude TB or MDR-TB. Retain priority specimens for culture and phenotypic drug susceptibility testing, and use validated molecular methods for additional resistance markers when indicated. A rapid rifampicin-resistance result is not the endpoint: reconcile it with culture, confirm the patient’s treatment history and communicate pending susceptibility results. Defined pathways with state or territory TB programs and a reference laboratory prevent results from disappearing between shifts. Regardless of the result, maintain airborne precautions and clinical review until the patient’s care team has assessed transmission risk and treatment.
Consumables and reagents need a different control because a stockout can interrupt both rapid testing and culture. The GLI consumables inventory checklist can guide forecasting, minimum levels, expiry surveillance, storage conditions and allocation when demand rises. Include cartridge availability, sample containers, transport materials, personal protective equipment and backup supply arrangements for remote sites. Review actual usage monthly and during periods of increased TB demand, then assign responsibility for contacting suppliers and notifying clinicians of any unavoidable testing interruption.
Control biohazards through the diagnostic pathway
Mycobacterial specimens require a documented local risk assessment, fit-for-purpose containment, training and supervision; a priority label must never relax handling controls. Use the applicable requirements of AS/NZS 5133 and organisational biosafety procedures, restrict access, keep specimen movement controlled and ensure staff know how to manage a spill or exposure. Pre-analytical checks, sealed transport containers and a clean-to-dirty workflow reduce cross-contamination risks. High-priority status can determine sequence and staffing, but it does not change the requirement to process every potentially infectious sample safely.
Waste management should be planned around the full diagnostic pathway, including sputum containers, cartridges, contaminated consumables and equipment used for smear preparation. The GLI guide on a biohazard waste plan can support local procedures for segregation, storage, treatment and disposal. Link the plan to cleaning schedules, transport manifests and contractor requirements, then test the process during an audit or drill. Untreated clinical waste must not be placed in ordinary general-waste streams, and the disposal route must remain valid during reduced staffing or increased testing demand.
Keep results traceable and actionable
Use unique barcodes or equivalent identifiers to connect the request, each sputum container, accessioning, instrument run, result, interpretation and final report. The laboratory information system should preserve user names, timestamps, repeat testing, comments and changes so a supervisor can reconstruct why a specimen was prioritised. Record the requested tests, turnaround category, clinical priority, sample condition and any corrective action. Where laboratories use electronic health-record links, patient identity matching still needs confirmation because duplicate names, aliases and migrated records can cause a critical result to reach the wrong record.
Critical results require a closed communication loop. Name the authorised person who receives a positive M. tuberculosis or rifampicin-resistance result, the expected time for acknowledgement and the escalation path when contact fails. Notify the clinician and relevant public-health authority according to jurisdictional requirements, and document the advice given about airborne isolation, specimen collection and treatment review. In remote settings, scheduled courier runs and after-hours contacts should be specified rather than assumed. An unreturned call, unread result or unrecorded handover should enter the laboratory’s incident and deviation system and be reviewed for system causes.
Monitor performance and strengthen the system
Choose indicators that reflect patient care as well as bench activity. Track time from collection to receipt, receipt to rapid-test result, receipt to culture confirmation and final drug susceptibility reporting, stratified by priority lane and originating site. Review invalid rates, specimen rejection, repeat testing, missed notifications, critical-call closure, stockouts, courier delays and discrepancies between rapid and conventional results. Compare sites without using the figures to punish teams serving smaller or remote populations; use them to expose bottlenecks and allocate support. Quarterly review meetings should include laboratory staff, clinicians, infection prevention, logistics and public-health representatives.
Map the workflow to the GLI Quality Tool’s four phases and twelve Quality Systems Essentials. Essentials such as safety, personnel, equipment, documents and records, assessment and continual improvement reveal different failure points, from an unqualified operator to an uncontrolled reagent or a closed-loop report that cannot be audited. Download the GLI quality resources, then select the checklists and templates that match the current phase of your quality management system. Start with one specimen stream, test the workflow under realistic demand, and expand only after the data show that urgent and routine work remain reliable.
Publish the priority definition, specimen acceptance criteria, rapid-test pathway, critical-result contacts, waste route and stock contingency in one controlled document accessible to every shift. Train reception staff, scientists, supervisors and after-hours operators together, then run a short simulation using a high-priority sputum request from a regional hospital. Record what was delayed or ambiguous, assign corrective actions and recheck the same steps after they are embedded in routine work.
Make the pathway operational now: open the GLI download area, select materials that fit your current quality-system phase, and place the chosen checklist beside the bench records. A dependable triage process gives urgent specimens speed without granting them permission to bypass safety, quality or public-health responsibilities, and it leaves every laboratory team with a clear, auditable route from collection to treatment decisions.